Please assess the completion status of the following clinical trial:

Trial Title: Maraviroc Switch Collaborative Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Documented HIV-1 infection by a licensed diagnostic test at any time prior to study entry~* Age \>18 years~* HIV-1 RNA \<200 copies/mL plasma for at least 24 weeks~* Stable (\>24 weeks) ART including two N(t)RTIs and a PI/r~* No evidence of any primary HIV genotypic mutations in HIV reverse transcriptase or protease for all patients with available resistance testing results conducted prior to cART and/or during viral rebound/failure~* Provision of written, informed consent.~Exclusion Criteria:~* CXCR4 or CCR5/CXCR4 dual tropic HIV tropism or a non-reportable tropism result based on assessment using proviral DNA~* Anticipated need to modify current cART regimen for toxicity management in the next 6 months~* The following laboratory criteria,~  1. absolute neutrophil count (ANC) \<750 cells/µL~ 2. haemoglobin \<8.0 g/dL~ 3. platelet count \<50,000 cells/µL~ 4. serum AST, ALT \>5 x upper limit of normal (ULN)~* Active hepatitis B co-infection~* Pregnant women or nursing mothers~* Current use of any prohibited medications as described in product specific information.~* Hypersensitivity to soy or peanuts~* Acute therapy for serious infection or other serious medical illness (in the judgement of the site Principal Investigator) requiring systemic treatment and/or hospitalisation~* Use of immunomodulators (e.g. systemic corticosteroids, recombinant interleukin-2, interferon) within 30 days prior to screening~* Patients with current alcohol or illicit substance use that in the opinion of the site Principal Investigator would conflict with any aspect of the conduct of the study~* Patients unlikely to be able to remain in follow-up for the protocol-defined period~* Prisoners or subjects who are compulsorily detained (involuntary incarcerated).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- No change (Type: NO_INTERVENTION): continue their current cART regimen
- Replace N(t)RTI drugs with Maraviroc (Type: ACTIVE_COMPARATOR): Replace N(t)RTI drugs with MVC at a dose of 150mg bid (MVC 300mg bid can be used at the discretion of the Investigator if the PI/r is fosamprenavir/r) and continue the PI/r
- Replace PI/r drugs with Maraviroc (Type: ACTIVE_COMPARATOR): Replace PI/r drugs with MVC at a dose of 300mg bid and continue 2N(t)RTI.

Based on this trial design, predict the completion outcome and termination type (if applicable).